18 Sep, 2018, 06:00 ET
SAINT-LAURENT, QC, Sept. 18, 2018 /CNW Telbec/ - Canbridge Sciences Inc. ("Canbridge Sciences") announced today that it has entered into a multi-year agreement with Axcelon Dermacare Inc. (ADI) for the exclusive distribution of Nanoderm® (Xylinum Nanofibrillar Cellulose) in Canada.
Nanoderm® is a unique bioengineered microfiber dressing made of pure cellulose and it is indicated for a variety of wound treatments including chronic ulcers, burns and dermabrasions. In most cases, it is a one-time dressing application.
"Chronic ulcers are debilitating. They may have a prolonged duration and are associated with a high rate of recurrence. Patients should have access to an array of treatment options to be able to manage non-healing ulcers", said Dr. Gaston Dumais, Canadian Dermatologist based in Montreal, Quebec.
"The reimbursement of Nanoderm® by public and private plans as an additional wound dressing in our treatment arsenal will be crucial to ensure adequate access for patients", he added.
"We are very pleased to have Nanoderm® in our portfolio of dermatology products as we believe it represents a breakthrough and cost-effective technology for the treatment of burns and chronic ulcers, including diabetic foot and venous leg ulcers" said Fakher Aissa, President of Canbridge Sciences. "We will be focusing our efforts on improving access to Nanoderm® by working with key stakeholders to ensure the product is adequately reimbursed by key public and private insurance plans", he added.
"We are delighted to enter into this relationship with Canbridge Sciences which has unique expertise in medical devices commercialization and health products reimbursement," said Mei Xu, President of ADI.
Nanoderm® is a Canadian bioengineered microfiber based film of pure cellulose indicated for the treatment of wounds and burns. The safety and efficacy of biocellulose based wound dressing have been demonstrated in multiple comparative open-label trials versus well-established standard dressings such as hydrocolloids and petrolatum gauzes1,2. Nanoderm® is designed as a one-time application in most cases, making it a desirable cost-effective option to help reduce health care costs and optimize caregivers' time and resources as they manage complex wounds. Nanoderm® is authorized for sale in Canada. It is indicated in low to medium exudating wounds where there is a loss of epithelium such as diabetic foot ulcers, second degree burns, dermabrasions, donor areas of graft tissue, Ulcerations of varied etiology, injuries caused by incisions, contusions or a combination of both. For more information visit www.nanoderm.ca
1- Slezak et al. Medical Engineering & Physics 26 (2004) 53–60 Evaluation of the efficiency of venous leg ulcer treatment with a BioCellulose Membrane dressing.
2- Solway DR et al. Int Wound J 2011; 8:69–73A parallel open-label trial to evaluate Microbial Cellulose (MC) wound dressing in the treatment of diabetic foot ulcers.
About Canbridge Sciences :
Canbridge Sciences is a Canadian pharmaceutical and medical devices company based in Montreal, QC with core capabilities in commercialization and products reimbursement. Its marketed product portfolio and pipeline are primarily focused on the field of specialty dermatology. Its mission is to make first and best-in-class innovative health interventions available to Canadians. To achieve this important goal, they partner with national and international leading pharmaceutical and medical device companies through their commercialization and market access divisions.
For more information visit www.canbridge-sciences.com
About Axcelon Dermacare:
Axcelon is a private company developing bacterial cellulose based products for biomedical devices as well as for non-medical applications. Nanoderm® is manufactured in Canada by ADI's strategic partner, ZBX Corporation of Toronto.
® Nanoderm† is a Registered trademark of Axcelon Dermacare Inc. (ADI) Distributed by Canbridge Sciences Inc. under license from ADI.
† Canbridge Sciences is a registered trademark of Canbridge Sciences Inc. in Canada.
SOURCE Canbridge Sciences Inc.
For further information: Media Contact: Fakher Aissa, President, Canbridge Sciences Inc., Tel: 1 (514) 312-0133 ext 4413, Email: [email protected]
Share this article